NGM Biopharmaceuticals, Inc. (NGM) has an overall financial health rating of B- with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-04-04.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-04-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-02 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-04-01 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-28 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-27 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-26 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-25 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-21 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-20 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-03-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
